Physician profile
Robert L Fine
NPI 1255499935
$7,291.00
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $1,669 · 2023: $3,132 · 2024: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,808 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,808.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $476.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $2,125.00 | 2023-2024 | Brukinsa |
| Lantheus Medical Imaging, INC. | $675.00 | 2023 | |
| Beigene, LTD. | $550.00 | 2024 | Brukinsa |
| Halozyme INC | $545.00 | 2024 | |
| Sanofi-Aventis U.S. LLC | $531.00 | 2020 | |
| Illumina, INC. | $476.00 | 2023 | Oncology Testing |
| Dr.Reddy'S Laboratories,INC. | $474.00 | 2024 | |
| Tersera Therapeutics LLC | $439.00 | 2023 | |
| Sentynl Therapeutics, INC. | $425.00 | 2020 | |
| Cepheid | $413.00 | 2020 | |
| Baxter Healthcare | $338.00 | 2019 | |
| Genzyme Corporation | $300.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.